Keywords: Roche, taspoglutide, Ipsen, Diabetes, Research

Roche/Ipsen’s taspoglutide meets Ph III primary endpoints against Lantus and placebo in patients with high BMI

Article | 18 December 2009

Print This

Swiss drug major Roche has announced headline results from the fourth and fifth of eight T-emerge Phase III studies involved ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in